ASCO GU 2018: A Randomized Phase III Double-Blind Clinical Trial (S1600) Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
San Francisco, CA (UroToday.com) This phase III trial will compare the impact of consuming Specialized IMmuno-nutrition (SIM) to oral nutritional support on postoperative complications after radical cystectomy. SIM is fortified with nutrients (L-arginine, omega-3 fatty acids, dietary nucleotides, and vitamin A), that have been shown to have immediate effects on immune and inflammatory responses, muscle sparing, and wound healing after surgery.
ASCO GU 2018: Evaluation of a 29 Gene Classifier for Basal/Non Basal Prediction in Muscle-Invasive Bladder Cancer FFPE Samples
San Francisco, CA (UroToday.com) Recent and independent muscle-invasive bladder cancer (MIBC) molecular classifications identified the basal / squamous-like (BASQ) tumors as an intrinsic and robust subtype, harboring a poor outcome and a possible chemo-sensitivity to cisplatin based regimen. The authors presented a study aimed to evaluate the diagnostic accuracy of a Nanostring classifier for tumor subtype prediction on fresh frozen plasma embeded (FFPE) specimens.
ASCO GU 2018: Role of Immunotherapy in Patients Undergoing Radiation Therapy for Bladder Cancer
San Francisco, CA (UroToday.com) Dr. Abhishek Solanki from Chicago presented the role of immunotherapy in patients undergoing radiation therapy for bladder cancer. Dr. Solanki notes that the classic radiation therapy mechanism includes: (i) direct effects – DNA double strand breaks leading to mitotic and apoptotic cell death and (ii) indirect effects – generation of free radicals leading to DNA double strand breaks leading to mitotic and apoptotic cell death. Radiation leads to release of tumor antigens and damage associated molecular patterns, which subsequently leads to antigen presenting cell activation, migration to lymph nodes and T-cell activation.
ASCO GU 2018: Best of Journals: Urothelial Carcinoma - Medical Oncology
San Francisco, CA (UroToday.com) Dr. Andrea Apolo, a medical oncologist form the National Cancer Institute presented multiple high-impact journal articles from the last 13 months that are particularly important to medical oncologists. She believes we are in the “golden era” of the development of systemic therapy for patients with advanced urothelial carcinoma.
ASCO GU 2018: Nivolumab Plus Ipilimumab Versus Standard of Care with Previously Untreated Unresectable or Metastatic Urothelial Carcinoma
San Francisco, CA (UroToday.com) Dr. Matt Galsky discussed the CheckMate 901 phase III randomized trial assessing nivolumab plus ipilimumab or standard of care vs standard of care alone in patients with previously treated metastatic urothelial carcinoma.
ASCO GU 2018: RNA-sequencing to Identify Three Different Molecular Grades and Immune Checkpoint Cascades with Distinct Clinical Behavior in NMIBC
San Francisco, CA (UroToday.com) Dr. Thenappan Chandrasekar from Toronto presented his rapid fire abstract this afternoon at GU ASCO 2018, discussing RNA-sequencing (RNA-sec) for the development of different molecular grades and immune checkpoint cascades among patients with non-muscle invasive bladder cancer (NMIBC).
ASCO GU 2018: The Role of Metastatic Burden in Cytoreductive/Consolidative Radical Cystectomy
San Francisco, CA (UroToday.com) At this afternoon’s poster session at GU ASCO, Dr. Roger Li presented on the role of metastatic burden with regard to the role of cytoreductive/consolidative radical cystectomy. The strategy of surgical extirpation of the primary tumor in the setting of metastatic disease has gained acceptance for a variety of solid tumors.